Vanguard Group
LABP

Vanguard Group’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Vanguard Group’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,400
Closed -$7.15K – 4606
2023
Q1 		$7.15K Sell
2,400
-7,909
-77% -$29.2K ﹤0.01% 4545
2022
Q4 		$51.6K Sell
10,309
-6,352
-38% -$24.3K ﹤0.01% 4444
2022
Q3 		$108K Buy
16,661
+3,905
+31% +$33.9K ﹤0.01% 4484
2022
Q2 		$93K Sell
12,756
-3,144
-20% -$28.6K ﹤0.01% 4556
2022
Q1 		$234K Sell
15,900
-14,580
-48% -$371K ﹤0.01% 4516
2021
Q4 		$1.46M Buy
30,480
+1
+0% +$105 ﹤0.01% 4150
2021
Q3 		$4.45M Sell
30,479
-40
-0.1% -$5.19K ﹤0.01% 3732
2021
Q2 		$3.52M Buy
30,519
+11,673
+62% +$1.3M ﹤0.01% 3766
2021
Q1 		$1.81M Buy
+18,846
New +$2.46M ﹤0.01% 3884

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's LABP Position: Q2 2023 in Review

Vanguard Group sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 2,400 shares — an estimated $7.15K sold.

Vanguard Group first reported a position in LABP in Q1 2021 and held it in 9 quarters. The position peaked at $4.45M in Q3 2021. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

  • Vanguard Group reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Vanguard Group sold 2,400 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $7.15K.
  • Vanguard Group first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Vanguard Group's Landos Biopharma, Inc. Common Stock position peaked at $4.45M in Q3 2021.
  • 8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.